Cubist Systematic Strategies, LLC Ngm Biopharmaceuticals Inc Transaction History

Cubist Systematic Strategies, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.17 - $1.92 $18,614 - $30,547	15,910 New	15,910 $25,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $35,793 - $114,879	34,089 New	34,089 $36,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $264,949 - $384,604	-71,223 Reduced 51.23%	67,793 $276,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $218,301 - $827,752	64,018 Added 85.36%	139,016 $697,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $1.35 Million - $1.89 Million	-106,988 Reduced 58.79%	74,998 $981,000
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $1.07 Million - $1.76 Million	100,816 Added 124.2%	181,986 $2.33 Million
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $282,607 - $380,630	20,464 Added 33.71%	81,170 $1.24 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $369,743 - $471,712	21,422 Added 54.53%	60,706 $1.08 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $372,049 - $483,572	18,464 Added 88.68%	39,284 $826,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $121,519 - $242,312	8,069 Added 63.28%	20,820 $411,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $270,416 - $345,514	10,821 Added 560.67%	12,751 $371,000
Q4 2020 Feb 16, 2021	SELL	$16.21 - $31.44 $110,519 - $214,357	-6,818 Reduced 77.94%	1,930 $58,000
Q3 2020 Nov 16, 2020	SELL	$15.59 - $19.97 $132,764 - $170,064	-8,516 Reduced 49.33%	8,748 $139,000
Q2 2020 Aug 14, 2020	BUY	$11.97 - $23.47 $194,584 - $381,528	16,256 Added 1612.7%	17,264 $341,000
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $10,080 - $19,666	1,008 New	1,008 $12,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.